DakoCytomation and Epitomics announce license and development agreement concerning rabbit monoclonal antibodies
DakoCytomation A/S, the leading global provider of in vitro diagnostic systems for Anatomic Pathologists, announced it entered into a license and a development agreement with Epitomics, Inc, the founder of rabbit monoclonal antibody technology. Terms of the license agreement grant DakoCytomation worldwide commercial rights to rabbit monoclonal antibodies currently developed by Epitomics. Additionally, under the development agreement Epitomics will design novel rabbit monoclonal antibodies for DakoCytomation to globally commercialize on a co-exclusive basis.
DakoCytomation's CEO Jes Ostergaard is enthusiastic about this partnership, stating, "The collaboration with Epitomics gives us access to a new technology that is tailored to supplement our existing portfolio of high quality antibodies. The more of these technologies that we have access to, the better system solutions we can provide for our customers in the Pathology Laboratories".
"In keeping with our corporate objectives, we will aggressively deploy the technologies that are necessary to expand our offerings and strengthen our ability to provide the best and most reliable tests worldwide. However, the quality and consistency of our primary antibodies remains the foundation on which we base our systems. We feel that this agreement is an opportunity to further strengthen our capabilities in this fundamental area" says Dennis Chenoweth, Corporate Vice President of Diagnostics.
DakoCytomation is eager to utilize its strong market knowledge as well as its extensive distribution and customer network to provide the global diagnostics community with cutting edge reagents such as rabbit monoclonal antibodies. Epitomics' unique high performance and high quality rabbit monoclonal antibodies will greatly augment DakoCytomation's broad portfolio of high quality reagents for in vitro diagnostics.
"The collaboration with DakoCytomation once again demonstrates the market acceptance of Epitomics robust rabbit monoclonal antibody technology," said Epitomics' CEO Dr. Guo-Liang Yu. "We are looking forward to seeing the utilization of our technology to benefit doctors and patients through the collaborations like the ones we have had with DakoCytomation."
Other news from the department business & finance
These products might interest you
Micro-Dx™ CE IVD by Molzym
Fully automated from sample to PCR analysis
Rapid identification of bacteria and fungi without time-consuming cultivation
DNA-free Taq Polymerases and Mastermixes by Molzym
DNA-free reagents for unrivalled sensitivity in molecular biology
Purity that makes the difference
Greener Alternative Products by Merck Life Science
Sustainable laboratory products for environmentally conscious research
Over 2,500 ecological alternatives to reduce your laboratory footprint
CellGenix® Growth Factors and Cytokines by Sartorius
Recombinant growth factors without animal products
Optimised cell culture for T cells and MSCs in gene therapy
Recombumin® Elite by Sartorius
ICHQ7 cGMP-compliant albumin for biotechnological applications
Increase consistency and safety for gene therapies and vaccines
DNA/RNA Shield™ SafeCollect Collection Kits by Zymo Research
Sample collection devices for simple & safe at-home testing
Best user experience for secure self-collection
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
